MULTICENTER STUDY OF LOW-DOSE ANTI-CD20 VELTUZUMAB FOR TREATMENT OF RELAPSED IMMUNE THROMBOCYTOPENIA

被引：0
|
作者：
Wegener, A. [1 ]
Liebman, H. A. [2 ]
Saleh, M. N. [3 ]
Abassi, R. [4 ]
Bussel, J. [5 ]
Cosgriff, T. M. [4 ]
Horne, H. [1 ]
Wolffgram, T. [6 ]
Goldenberg, D. M. [1 ]
机构：
[1] Immunomedic Inc, Morris Plains, NJ USA
[2] USC, Keck Sch Med, Los Angeles, CA USA
[3] Georgia Canc Specialists, Atlanta, GA USA
[4] Hematol Oncol Specialists, Denville, NJ USA
[5] NY Presbyterian Hosp, New York, NY USA
[6] Nycomed GmbH, Constance, Germany
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0227
引用
收藏
页码：90 / 90
页数：1
相关论文
共 50 条
  • [1] Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP)
    Saleh, Mansoor N.
    Liebman, Howard
    Bernstein, Zalc P.
    Negrea, O. George
    Bussel, James B.
    Onyegbula, Anthony C.
    Farber, Charles M.
    Abassi, Rashid
    Cosgriff, Thomas M.
    Pennington, Kenneth
    Horne, Heather
    Teoh, Nick
    Gomaa, Asraf
    Wegener, William A.
    Goldenberg, David M.
    BLOOD, 2009, 114 (22) : 541 - 541
  • [2] Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia
    Liebman, Howard A.
    Saleh, Mansoor N.
    Bussel, James B.
    Bernstein, Zale P.
    Negrea, O. George
    Onyegbula, Anthony C.
    Farber, Charles M.
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    BLOOD, 2011, 118 (21) : 1420 - 1420
  • [3] Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study
    Liebman, Howard A.
    Saleh, Mansoor N.
    Bussel, James B.
    Negrea, Ovidiu George
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (05) : 693 - 701
  • [4] Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia
    Liebman, Howard A.
    Saleh, Mansoor N.
    Bussel, James B.
    Negrea, O. George
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    HAEMATOLOGICA, 2016, 101 (11) : 1327 - 1332
  • [5] Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study
    Liebman, Howard
    Bussel, James B.
    Saleh, Mansoor N.
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    BLOOD, 2013, 122 (21)
  • [6] A Novel Anti-CD20 Monoclonal Antibody for Treating Relapsed Immune Thrombocytopenia
    Liu, Jia
    Yao, Han
    Tao, Jun
    Feng, Yimei
    Zhang, Xi
    BLOOD, 2024, 144
  • [7] A fixed, low dose of anti-CD20 antibody (Rituximab) is an effective treatment for patients with chronic immune thrombocytopenia
    El-Najjar, I
    Rule, SAJ
    Nokes, TJC
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 79 - 80
  • [8] Low-Dose Humanized Anti-CD20 Monoclonal Antibody (MAb), Veltuzumab, in Adult Immune Thrombocytopenic Purpura (ITP): Initial Results of a Phase I/II Study
    Liebman, Howard A.
    Saleh, Mansoor N.
    Abassi, Rashid
    Cosgriff, Thomas M.
    Teoh, Nick
    Leoni, Matthew J.
    Wegener, William
    Goldenberg, David M.
    BLOOD, 2008, 112 (11) : 1170 - 1170
  • [9] VELTUZUMAB Humanized Anti-CD20 Monoclonal Antibody Oncolytic
    Bhat, S. A.
    Czuczman, M. S.
    DRUGS OF THE FUTURE, 2011, 36 (07) : 519 - 526
  • [10] Subcutaneous Veltuzumab, a Humanized Anti-CD20 Antibody, in the Treatment of Refractory Pemphigus Vulgaris
    Ellebrecht, Christoph T.
    Choi, Eun J.
    Allman, David M.
    Tsai, Donald E.
    Wegener, William A.
    Goldenberg, David M.
    Payne, Aimee S.
    JAMA DERMATOLOGY, 2014, 150 (12) : 1331 - 1335
12345